Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 5Phase 1/2 3Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 10Multiple Myeloma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Hodgkin Disease 5Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma 4Hematologic Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Primary Myelofibrosis 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Leukemia, Plasma Cell 2Burkitt Lymphoma 2Thalassemia 1Skin Neoplasms 1Polycythemia Vera 1Peritoneal Tumor 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Hematological Malignancies 1Mesothelin-positive Advanced Malignant Solid Tumors 1

Interventions

fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 6Cyclosporine 6Busulfan 6Mycophenolic Acid 5Cyclophosphamide 5Antilymphocyte Serum 5Methotrexate 4Filgrastim 4Whole-Body Irradiation 3Radiotherapy 3Aprepitant 3Therapeutics 2Tacrolimus 2Ondansetron 2Methylprednisolone 2Melphalan 2Flow Cytometry 2Dexamethasone 2Cord Blood Stem Cell Transplantation 2Calcium Dobesilate 2thymoglobulin 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1Voriconazole 1Thiotepa 1Sugars 1Psychiatric Rehabilitation 1Pravastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Leukemia, Myelomonocytic, Chronic × fludarabine × Clear all
NCT07588594 2026-05-26

Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia

Peking University People's Hospital

Phase NA Recruiting
31 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡